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Abstract
We present a multifunctional nanoparticle platform that has targeting moieties shielded by a
matrix metalloproteinase-2 (MMP2) cleavable PEG coating. Upon incubation with MMP2 this
surface-switchable coating is removed and the targeting ligands become available for binding. The
concept was evaluated in vitro using the biotin and αvβ3-integrin-specific RGD-peptide
functionalized nanoparticles.
Intravenously administrable nanoparticles can be used in a variety of biomedical
applications that range from targeted drug delivery, target-specific imaging, nucleic acid
delivery to thermal therapy.1,2 The nanoparticle coating is of key importance as it greatly
influences pharmacokinetics and bioavailability as well as the nanoparticle’s ability to target
a diseased site.3 Polymeric coatings, such as a polyethylene glycol (PEG) coating, provide
shielding, reduce recognition and subsequent removal by the mononuclear phagocyte system
(MPS), and therefore are applied to the majority of nanoparticles used for intravenous
administration.1 To enhance specificity and induce nanoparticle uptake by cells, target-
specific molecules can be conjugated to the nanoparticle’s coating.1,2 However, the
exposure of targeting moieties at the surface may counteract the shielding effect of the
polymeric surface coating and can cause augmented recognition by the MPS. In addition,
off-target binding to epitopes expressed by vascular components such as endothelial or
circulating cells can also reduce accumulation of nanoparticles at their target site.
To deal with the aforementioned limitations of ligand functionalized nanoparticles we have
developed a highly flexible nanoemulsion (Fig. 1a), based on a previously reported
platform,4 of which the coating can be removed by matrix metalloproteinase-2 (MMP2).5
We have chosen for an MMP2 cleavable site as the enzyme is highly expressed at a variety
of pathological sites, including solid tumors and atherosclerotic plaques.6,7 Upon
nanoparticle accumulation at the pathological tissue and exposure to MMP2, the coating is
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‘removed’ and the targeting moieties become available for binding. The nanoemulsion core
consists of soybean oil and the coating is comprised of a mixture of cholesterol, PEG350
phospholipids (mPEG350-DSPE), PEG phospholipids functionalized with targeting moieties
(i.e. biotin or RGD functionalized PEG1000 lipids), as well as a MMP2 cleavable methoxy-
polyethylene glycol (PEG)-lipid (mPEG-MMP2p-DSPE, Fig. 1b) to provide shielding. A
description of the synthesis of the nanoemulsion and mPEG-MMP2p-DSPE is provided in
the Supporting Information.
As a model for targeting and to robustly demonstrate the effect of shielded versus
unshielded nanoemulsions we designed experiments where plain nanoemulsions, which had
biotin-PEG1000-DSPE and the non-cleavable mPEG3000-DSPE incorporated, were used.
Avidin, a 66 kDa protein with 4 binding sites for biotin, can induce nanoparticle
aggregation, if the nanoparticles are unshielded and biotin is exposed, and can therefore
serve as a model for targeting. By varying the lipid composition of the corona (cholesterol,
mPEG350-DSPE, mPEG3000-DSPE, and biotin-PEG1000-DSPE) we were able to create
nanoemulsions with different coating types (Table S.1). The avidin-induced aggregation was
monitored with dynamic light scattering (DLS), while targeting of Rhodamine labeled
nanoemulsions was evaluated on an avidin coated 96-well plate using a plate reader (Fig.
S1, S2).
Surface switchable nanoemulsions were obtained by incorporation of mPEG-MMP2p-DSPE
into the formulation. Based on the aforementioned model aggregation and binding
experiments, we prepared nanoemulsions using the minimum of 10% PEG shielding
(thereby permitting maximum MMP2 access to the cleavable peptide), 2.5% biotin to ensure
good binding to avidin, and optionally replacing the uncleavable mPEG3000-DSPE by the
MMP2 cleavable lipid mPEG-MMP2p-DSPE (Table S.2). Through HPLC analysis we
evaluated the nanoparticle composition after synthesis (Fig. S.10), which was found to be
very similar to the starting phospholipid mixture (Table S.3), thereby proving the integrity of
the nanoemulsion synthesis.
The nanoemulsions were left untreated or treated with MMP2 before conducting aggregation
or binding experiments. We observed that mPEG-MMP2p-DSPE containing nanoemulsions
that were not pre-incubated with MMP2 (Fig. 2a) or that were incubated with inactive
MMP2 (Fig. S.11) did not aggregate upon incubation with avidin, similar to the control
nanoemulsions that contained either 10% or 20% mPEG3000-DSPE (Fig. S.2a). Conversely,
MMP2-treated mPEG-MMP2p-DSPE containing nanoemulsions did aggregate and the
relative particle size was found to increase by a factor 2 to 3, similar to the control
nanoemulsions with the freely exposed biotin-PEG-DSPE (and 0% mPEG3000-DSPE) (Fig.
2a). MMP2 dose effects on the cleavage are shown in Fig. S.12.
To mimic binding to epitopes expressed at cells, we performed binding experiments with an
avidin monolayer using the same samples and conditions as for the above-described
aggregation experiment. To that end we used avidin coated 96-well plates and incubated the
wells with the different samples for 30 min. Rhodamine labeled phospholipids were
included in the lipid corona of the nanoemulsions so that their binding could be measured by
recording the fluorescence with a plate reader. Similar to the aggregation experiment, and in
line with the aforementioned hypothesis, we observed binding for the unshielded control
nanoemulsions and, crucially, for the mPEG-MMP2p-DSPE nanoemulsions that were
pretreated with MMP2 (Fig. 2b).
In a further evaluation of the nanoemulsion binding characteristics, we developed a self-
assembled monolayer (SAM) method that enabled the functionalization of gold-silicon (Au-
Si) wafers with avidin and imaging with atomic force microscopy (AFM). The 2D-AFM
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image in Fig. 3c clearly shows elevated binding of mPEG-MMP2p-DSPE containing
nanoemulsion treated with MMP2 to the surface as compared to the control sample (Fig.
3b).
To confirm that the aggregation/binding was induced by cleaving of the mPEG2000 moiety
we performed mass spectrometry on mPEG-MMP2p-DSPE that was left untreated or
incubated with MMP2 for 12 hrs. Mass spectrometry revealed the mPEG2000 cleavage
product in the sample incubated with MMP2 (Fig. S.13).
The kinetics of PEG cleavage was also investigated. To that end the nanoemulsions were
incubated with MMP2 for different time spans, ranging from 1 to 12 hours, while avidin-
induced aggregation was used as the readout method. As shown in Fig. S.14b, 12 hours of
MMP2 treatment was necessary to induce the ligand exposure. A similar timeframe has been
shown by others to induce the in vitro cleavage of cancer pro-drugs conjugated with MMP2
sensitive peptides.16 However, it is important to consider that in vitro conditions do not fully
reflect the in vivo situation. We purposely and carefully designed our nanoparticles to have a
PEG-density and ligand density that requires relatively long MMP2 exposure in order for the
PEG to be cleaved off. Indeed, in experiments where we have exposed the nanoemulsions to
serum protein (FBS), we have seen a high stability of the nanoparticles (Fig. S.15).
Protease induced nanoparticle aggregation has been suggested to be useful in medical and
biochemical assays as well as to preserve good pharmacokinetics of target-specific
nanoparticles.8,9 In for example tumor targeting, a number of epitopes of interest that are
expressed at tumor cells are also expressed by cells of the MPS and, more importantly, by
the diseased endothelium. An example of such an epitope is the αvβ3-integrin, which is an
excellent tumor vasculature marker for nanoparticle targeting,10 but targeting of this integrin
expressed at tumor cells is difficult as, upon intravenous administration, the nanoparticles
are exposed and bind to the vascular endothelium first and therefore can only marginally
extravasate into the tumor interstitium.11 Because RGD peptides are known to have a high
affinity for αvβ3-integrin, we have functionalized our platform with c[RGDfK]-DSPE (full
synthetic details are included in the Supporting Information). As for biotin-PEG1000-DSPE,
c[RGDfK]-DSPE has been designed such that the c[RGDfK] targeting units protrude from
the nanoemulsion platform after MMP2 cleavage of the mPEG-MMP2p-DSPE lipid.
Human umbilical vein endothelial cells (HUVEC) and breast cancer cells (MDA-MB-231),
that both are known to express high levels of αvβ3-integrin, as well as murine macrophage
(J774A1) were treated with RGD functionalized control nanoemulsions and surface
switchable nanoemulsions. Flow cytometry revealed a clear difference in nanoparticle-cell
association when the RGD moieties were available for targeting, i.e. at 0% mPEG3000 and
at 10% mPEG-MMP2p-DSPE after MMP2 treatment (Fig. 4).
Lastly, to examine the versatility of our nanoemulsion platform, we included either oleic
acid coated iron oxide (IO) or oleyl mercaptan coated gold (Au) nanocrystals as well as the
lipophilic drug simvastatin in mPEG-MMP2p-DSPE functionalized nanoemulsion samples
to render so-called theranostic nanoparticles, exhibiting both therapeutic and diagnostic
properties. In Supp. Fig. 20a and 20b we present DLS size and polydispersity measurements
as well as transmission electron microscopy (TEM) images of these theranostic
nanoemulsions. For the Au nanoemulsions the attenuation characteristics, measured in
Hounsfield Units (HU) per mM (SFig. 20a), revealed good CT contrast generating
properties (Fig. 5, top), similar to that of a clinically applied iodinated CT contrast agent
(Isovue, Bracco Diagnostic). As a measure for the IO nanoemulsion’s potential to serve as
an MRI contrast generating material we acquired the longitudinal and transverse relaxivities
r1 and r2 at 60 MHz (Supp. Fig. 20a). Clear MR hypo-intensities are generated by IO loaded
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nanoemulsions as is shown in Fig. 5 (bottom). The drug inclusion for the final Au
formulation was measured using 1H-NMR spectroscopy (Fig. S.21). Simvastatin
encapsulation efficiency (encapsulated drug/input) was established to be 57.2% of the initial
input value, and the loading efficiency was 1.43% (weight drug/weight oil).
In summary we have presented a self-assembled and multifunctional nanoemulsion platform
that is surface-switchable upon exposure to MMP2. The inclusion of diagnostically active
materials and drugs is straightforward. We believe our nanoemulsion platform may be useful
in a variety of conditions that are associated with MMP2 (over)expression, including cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
(a) Schematic of the biotin functionalized and surface-switchable nanoemulsion platform.
(b) Structure of MMP2 cleavable mPEGMMP2p-DSPE (with mPEG being mPEG2000).
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Fig. 2.
(a) Avidin-induced aggregation of biotin functionalized nanoemulsions. Nanoparticle
relative size was measured by DLS. (b) Nanoemulsion binding to an avidin monolayer.
Normalized fluorescence of unshielded control nanoemulsions, as well as non-treated and
MMP2-treated surface-switchable nanoemulsions. Mean ± SD (N=3). § vs 10% PEG-
shielded 2.5% biotin nanoparticles (P≤ 0.05), ⌘ vs 10% PEG-MMP2p-shielded 2.5% biotin
nanoparticles before MMP2 treatment (P≤ 0.05).
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Fig. 3.
Typical 2D-AFM images of Au-Si wafers after incubation with (a) avidin only, (b) avidin
and then a 10% mPEG3000-DSPE with 2.5% biotin-PEG1000-DSPE nanoemulsion and (c)
avidin and then a 10% mPEG-MMP2p-DSPE with 2.5% biotin-PEG1000-DSPE
nanoemulsion previously treated with MMP2.cells incubated with (i) 0% m PEG3000 and
2.5% RGD nanoemulsions, (ii) 10% mPEG3000 and 2.5% RGD nanoemulsions and (iii)
10% PEG-MMP2p nanoemulsion phantoms.
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Fig. 4.
Flow cytometry histograms of HUVEC, MDA MB 231 and J774A1 cells incubated with (i)
0% mPEG3000 and 2.5% RGD nanoemulsions, (ii) 10% mPEG3000 and 2.5% RGD
nanoemulsions and (iii) 10% PEG-MMP2p and 2.5% RGD nanoemulsions after MMP2
treatment.
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Fig. 5.
CT (top) and MR (bottom) images of Au and IO theranostic nanoemulsion phantoms.
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